Literature DB >> 9467211

Toxic digoxin-drug interactions: the major role of renal P-glycoprotein.

G Koren1, C Woodland, S Ito.   

Abstract

The clinical use of digoxin is complicated by a large number of drug interactions leading to severe toxicity of the cardiac glycoside. The discovery that digoxin is actively secreted by the renal tubular cell via the p-glycoprotein drug efflux pump has led us to examine whether commonly interacting drugs do so by inhibiting renal tubular secretion of digoxin. We review digoxin-drug interactions which have been studied kinetically in humans, where there are sufficient data on renal clearance of digoxin and GFR.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9467211

Source DB:  PubMed          Journal:  Vet Hum Toxicol        ISSN: 0145-6296


  10 in total

Review 1.  The role of diet on the clinical pharmacology of oral antineoplastic agents.

Authors:  Antonio Ruggiero; Maria G Cefalo; Paola Coccia; Stefano Mastrangelo; Palma Maurizi; Riccardo Riccardi
Journal:  Eur J Clin Pharmacol       Date:  2011-07-28       Impact factor: 2.953

2.  Exposure of LS-180 cells to drugs of diverse physicochemical and therapeutic properties up-regulates P-glycoprotein expression and activity.

Authors:  Alaa H Abuznait; Shawn G Patrick; Amal Kaddoumi
Journal:  J Pharm Pharm Sci       Date:  2011       Impact factor: 2.327

3.  Population pharmacokinetic model of digoxin in older Chinese patients and its application in clinical practice.

Authors:  Xiao-dan Zhou; Yan Gao; Zheng Guan; Zhong-dong Li; Jun Li
Journal:  Acta Pharmacol Sin       Date:  2010-06       Impact factor: 6.150

Review 4.  Clinical pharmacokinetics of ranolazine.

Authors:  Markus Jerling
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

5.  Cytochrome P450 3A and P-glycoprotein drug-drug interactions with voclosporin.

Authors:  Spencer Y Ling; Robert B Huizinga; Patrick R Mayo; Richard Larouche; Derrick G Freitag; Launa J Aspeslet; Robert T Foster
Journal:  Br J Clin Pharmacol       Date:  2014-06       Impact factor: 4.335

Review 6.  Active ingredients in Chinese medicines promoting blood circulation as Na+/K+ -ATPase inhibitors.

Authors:  Ronald J Y Chen; Tzyy-rong Jinn; Yi-ching Chen; Tse-yu Chung; Wei-hung Yang; Jason T C Tzen
Journal:  Acta Pharmacol Sin       Date:  2011-02       Impact factor: 6.150

7.  Voriconazole does not affect the steady-state pharmacokinetics of digoxin.

Authors:  Lynn Purkins; Nolan Wood; Diane Kleinermans; Don Nichols
Journal:  Br J Clin Pharmacol       Date:  2003-12       Impact factor: 4.335

Review 8.  Membrane transporter proteins: a challenge for CNS drug development.

Authors:  François Girardin
Journal:  Dialogues Clin Neurosci       Date:  2006       Impact factor: 5.986

9.  Probing the stereoselectivity of OleD-catalyzed glycosylation of cardiotonic steroids.

Authors:  Xue-Lin Zhu; Chao Wen; Qing-Mei Ye; Wei Xu; Deng-Lang Zou; Guang-Ping Liang; Fan Zhang; Wan-Na Chen; Ren-Wang Jiang
Journal:  RSC Adv       Date:  2018-01-30       Impact factor: 4.036

10.  Cannabis constituents interact at the drug efflux pump BCRP to markedly increase plasma cannabidiolic acid concentrations.

Authors:  Lyndsey L Anderson; Maia G Etchart; Dilara Bahceci; Taliesin A Golembiewski; Jonathon C Arnold
Journal:  Sci Rep       Date:  2021-07-22       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.